Match!

Essential Elements of a Technology and Outcomes Assessment Initiative

Published on Sep 19, 2007in JAMA51.273
· DOI :10.1001/jama.298.11.1323
Ezekiel J. Emanuel81
Estimated H-index: 81
,
Victor R. Fuchs44
Estimated H-index: 44
,
Alan M. Garber63
Estimated H-index: 63
Sources
Abstract
THE MISMATCH BETWEEN US HEALTH EXPENDITURES AND the resources devoted to learning which health interventions are most effective is both striking and unwise. Each year US individuals spend more than 2 trillion on health care. More than 00 billion is spent for research and development and for regulatory approval of new technologies. Yet total spending on technology assessment almost certainly falls short of 1 billion per year— 0.05% of all US health care spending. Some of the trillion in health care expenditures buys services of little or no value. This waste has been attributed to misleading advertisements, media hype, misguided state and federal mandates, fear of malpractice litigation, misaligned reimbursement incentives, and generous insurance that encourages patients to ignore the cost of services. Efforts to curb the inappropriate use of medical technologies, however, can have only limited success unless they address the paucity of reliable information about their benefits, cost, and value. For decades, calls for more systematic assessment of medical technologies and outcomes have gone unheeded. Recently, however, federal legislators and officials have recognized that better information is imperative. The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 mandated research on “outcomes, comparative clinical effectiveness, and appropriateness of health care.” The former Medicare administrator, Gail Wilensky, has described alternative structures for a technology assessment organization. Representatives, senators, and presidential candidates have supported legislation to fund comparative effectiveness initiatives. Renewed interest in technology and outcomes assessment efforts can be traced to several factors: disillusionment with traditional cost-containment approaches, deepening anxiety about the safety and effectiveness of drugs and medical care, recognition that little is known about the optimal use of existing diagnostic procedures and treatments, and the explosion in health care expenditures anticipated as baby boomers age. By 2015, the number of US individuals in their 60s—a decade of heavy use of medical care— will increase by nearly 50%. Simultaneously, because of scientific advances, many new technologies will enter clinical practice. The combination of new technologies and greater use of older medical interventions are the fundamental drivers of increasing health care costs. Increasing health care costs have induced employers and insurance companies to shift more financial responsibility onto individuals through “consumer-directed” health plans and health savings accounts. In addition, private health plans, Medicare, and Medicaid are likely to urge hospitals and clinicians to become agents of cost control. Essential to these efforts to enhance quality and lower costs is comprehensive, objective information about the absolute and relative costs and benefits of medical interventions. Technology assessment in the United States has been hampered by pressure and limited resources. In the early 1990s, key federal agencies dedicated to technology assessment, such as the Congressional Office of Technology Assessment, were eliminated. Efforts by other federal agencies are fragmented and underfunded. The Department of Veterans Affairs, the National Institutes of Health, and the Centers for Medicare & Medicaid Services have little money for technology assessment. The mission of the Agency for Healthcare Policy and Research (AHCPR) was technology and outcomes evaluation. But, in 1994, when the AHCPR sponsored research showing that there was inadequate evidence to support commonly performed back operations, its funding was almost eliminated at the behest of disgruntled orthopedic and neurosurgeons and congressional critics of the Clinton health plan. While AHCPR survived, it was chastened. Its name was changed to the Agency for Healthcare Research and Quality and it has generally avoided controversial issues. Most importantly, little of its small budget—$320 million—is dedicated to evaluative research. State and private technology evaluation activities supplement federal efforts. In 1985, the Blue Cross and Blue Shield Association established the Technology Evaluation Center “for assessing medical technologies through comprehen-
  • References (17)
  • Citations (66)
📖 Papers frequently viewed together
257 Citations
1 Author (Alan M. Garber)
70 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
References17
Newest
21 CitationsSource
Interest in objective, credible comparative clinical effectiveness information has been growing in the United States, both by those who support competitive behavior in health care and by those who support administered pricing. The Medicare drug benefit has heightened interest in better information, although the potential payoff is even greater for medical procedures than for drugs, since procedures account for more of the health care dollar. Careful consideration needs to be given regarding the ...
138 CitationsSource
#1Christine BorgerH-Index: 3
#2Sheila SmithH-Index: 22
Last. M. Kent Clemens (Centers for Medicare and Medicaid Services)H-Index: 10
view all 7 authors...
Growth in national health spending is projected to slow in 2005 to 7.4 percent, from a peak of 9.1 percent in 2002. Private health insurance premiums are projected to slow to 6.6 percent in 2005, with a rebound expected in 2007. The introduction of Medicare Part D drug coverage in 2006 produces a dramatic shift in spending across payers but has little net effect on aggregate spending growth. Health spending is expected to consistently outpace gross domestic product (GDP) over the coming decade, ...
186 CitationsSource
The National Institute for Health and Clinical Excellence (NICE) was established as a part of the British National Health Service in 1999 to set standards for the adoption of new health care technologies and the management of specific conditions. In doing so it was required explicitly to take into account both clinical effectiveness and cost-effectiveness. This article describes how NICE has responded to the challenge and considers whether its experience of balancing quality, innovation, and val...
153 CitationsSource
#1James C. Robinson (University of California, Berkeley)H-Index: 41
The health savings account reflects a philosophical shift in emphasis from collective to individual responsibility for the management and financing of care. Dr. James Robinson explains that HSAs form the core of the emerging “consumer-directed” insurance plans, imposing greater cost sharing on enrollees but permitting broader choices.
41 CitationsSource
#1Susan C. Emmer (American Geriatrics Society)H-Index: 1
#2Laura Allendorf (American Geriatrics Society)H-Index: 1
The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (PL 108–73; MMA), signed into law in December 2003, represents the biggest expansion of Medicare in the program’s history. In addition to adding outpatient prescription drug coverage, the bill contains scores of other changes affecting the nation’s 40 million older and disabled Americans and the providers who care for them. Responsibility for implementing the complex law and educating beneficiaries about their new options...
136 CitationsSource
The primary contribution of Joseph Newhouse’s paper is to make the point that it is impossible to devise a drug pricing policy that satisfies either the conditions for economic efficiency or prevailing standards of “fairness.” Not specifically mentioned by Newhouse is a rule for the socially efficient outlays on selling and marketing by the pharmaceutical industry. In fact, it is not clear that the current allocation of the industry’s revenue dollars to marketing and R&D is efficient from societ...
36 CitationsSource
#1Bradford H. Gray (New York Academy of Medicine)H-Index: 5
#2Michael K. Gusmano (New York Academy of Medicine)H-Index: 16
Last. Sara R. Collins (New York Academy of Medicine)H-Index: 20
view all 3 authors...
ABSTRACT: The Agency for Health Care Policy and Research has had a turbulent history. Created with little opposition in 1989, it narrowly escaped being eliminated in 1995, only to be reauthorized (...
72 CitationsSource
#1Vidya SharmaH-Index: 19
#2M. Denise DowdH-Index: 19
Last. Stephen D. SimonH-Index: 30
view all 5 authors...
Objective To examine the association between mass media attention regarding invasive group A streptococcal (GAS) disease and testing for GAS in a pediatric emergency department (ED). Design, Setting, and Participants An observational analysis was performed of patients who had GAS tests done in a pediatric ED between December 1, 1999, and November 30, 2001. Data were analyzed by dividing each of the 2 years into 4 consecutive 90-day intervals. Data including age, date of the visit, presenting com...
30 CitationsSource
#1Reinhard Busse (European Observatory on Health Systems and Policies)H-Index: 44
#2Jacques OrvainH-Index: 4
Last. Claudia WildH-Index: 16
view all 11 authors...
Recommendations already exist on how to write a structured abstract for the INAHTA Database (http://agatha.york.ac.uk/htahp.htm). The abstract must be written in English. In 392 INTL. J. OF TECHNOLOGY ASSESSMENT IN HEALTH CARE 18:2, 2002 Best practice in undertaking and reporting HTA Table 15. Data To Be Included in an English Structured Abstract Title: first title in English, then original title in brackets Author/s: according to Vancouver style Organization: organization commissioning the repo...
168 CitationsSource
Cited By66
Newest
#1Calin CorciovaH-Index: 4
#2Doru AndritoiH-Index: 3
Last. C. LucaH-Index: 3
view all 4 authors...
Starting with the essential elements of medical equipment maintenance, a multitude of interdependent factors can be easily identified at all stages of medical equipment life, which, if neglected, greatly complicates the maintenance of the equipment, leading to high operating costs. If maintenance capabilities are considered at an early planning and purchasing stage, maintenance issues can be minimized. Proper maintenance throughout the life cycle of medical equipment involves all activities rela...
Source
#2D. AndriţoiH-Index: 2
Last. Radu CiorapH-Index: 5
view all 4 authors...
The provision of today’s health services depends on a steady increase in the evolution of medical technology. There is no hospital department that has not felt the impact of electronic, mechanical, hydraulic equipment in daily routine. The development of medical technology, the complexity of medical equipment has been rapid, producing a proliferation of growing medical devices. This paper was conducted to provide a comprehensive study evaluating the maintenance and repair program for medical equ...
Source
#1Damien C. Weber (Paul Scherrer Institute)H-Index: 42
#2Jean Louis HabrandH-Index: 2
Last. Anita MahajanH-Index: 36
view all 14 authors...
Radiotherapy plays an important role in the management of childhood cancer, with the primary aim of achieving the highest likelihood of cure with the lowest risk of radiation-induced morbidity. Proton therapy (PT) provides an undisputable advantage by reducing the radiation 'bath' dose delivered to non-target structures/volume while optimally covering the tumor with tumoricidal dose. This treatment modality comes, however, with an additional costs compared to conventional radiotherapy that could...
9 CitationsSource
Objectives: The aim of this study was to identify good practice principles for health technology assessment (HTA) that are the most relevant and of highest priority for application in Latin America and to identify potential barriers to their implementation in the region. Methods: HTA good practice principles proposed at the international level were identified and then explored during a deliberative process in a forum of assessors, funders, and product manufacturers. Results: Forty-two representa...
3 CitationsSource
#1Franz Hessel (SRH University Berlin)H-Index: 14
Trotz der vielversprechenden Hoffnungen, die in personalisierte Medizin und genetische Tests gesetzt werden, haben bisher nur wenige Biomarker-Tests Eingang in die Routineversorgung gefunden. Die Grunde hierfur sind vielfaltig, wobei vor allem die unklaren Wege in die Kostenerstattung durch die Sozialleistungstrager und die im Vergleich zu Arzneimitteln niedrigere wissenschaftliche Evidenz fur einen patientenrelevanten Zusatznutzen genannt werden. Seitens der Sozialleistungstrager besteht eine A...
Source
#1Arsen HovanesyanH-Index: 2
#2Eduardo RubioH-Index: 1
Last. Michael W. Rich (WashU: Washington University in St. Louis)H-Index: 76
view all 5 authors...
Cardiovascular services are the third largest source of Medicare spending. We examined the rate of cardiovascular service utilization in the community of Glendale, CA, compared with the nearest academic medical center, the University of Southern California. Publicly available utilization data released by Medicare for the years 2012 and 2013 were used to identify all inpatient and outpatient cardiology services provided in each practice setting. The analysis included 19 private and 17 academic ca...
1 CitationsSource
view all 3 authors...
#1Joseph B. Babigumira (UW: University of Washington)H-Index: 11
#2Alisa Jenny (UW: University of Washington)H-Index: 7
Last. Louis P. Garrison (UW: University of Washington)H-Index: 29
view all 5 authors...
Objectives Health technology assessment (HTA) for a wide range of healthcare technologies is an essential component of well-functioning health systems. Knowledge of the use of HTA in low- and middle-income countries (LMICs) is limited. Methods We performed a survey of HTA in selected LMICs. We interviewed key stakeholders on the use, conduct and challenges of performing HTA in their countries. We performed mixed-methods analyses to identify, characterize and describe HTA and how it relates to gr...
3 CitationsSource
#1J. Jaime CaroH-Index: 1
#2Jörgen MöllerH-Index: 10
Last. Jack IshakH-Index: 4
view all 5 authors...
Source
#1Dean A. Shumway (UM: University of Michigan)H-Index: 7
#2Kent A. Griffith (UM: University of Michigan)H-Index: 52
Last. James A. Hayman (UM: University of Michigan)H-Index: 44
view all 8 authors...
IMRT use grew significantly across the state of Michigan over time, with four-fold variability among centers, which was related to facility characteristics.
8 CitationsSource